Satoshi Yuki

2.2k total citations
129 papers, 1.1k citations indexed

About

Satoshi Yuki is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Satoshi Yuki has authored 129 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 119 papers in Oncology, 68 papers in Pulmonary and Respiratory Medicine and 23 papers in Surgery. Recurrent topics in Satoshi Yuki's work include Colorectal Cancer Treatments and Studies (97 papers), Gastric Cancer Management and Outcomes (52 papers) and Cancer Treatment and Pharmacology (24 papers). Satoshi Yuki is often cited by papers focused on Colorectal Cancer Treatments and Studies (97 papers), Gastric Cancer Management and Outcomes (52 papers) and Cancer Treatment and Pharmacology (24 papers). Satoshi Yuki collaborates with scholars based in Japan, United States and Switzerland. Satoshi Yuki's co-authors include Yoshito Komatsu, Takayuki Yoshino, Naoya Sakamoto, Kentaro Sawada, Takeharu Yamanaka, Eiji Shinozaki, Tomohiro Nishina, Atsushi Ohtsu, Kentaro Yamazaki and Yasutoshi Kuboki and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Satoshi Yuki

122 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Satoshi Yuki Japan	19	819	435	244	237	201	129	1.1k
Hidekazu Kuramochi Japan	19	626 0.8×	302 0.7×	272 1.1×	189 0.8×	247 1.2×	77	1.0k
Roger Sidhu United States	13	715 0.9×	388 0.9×	156 0.6×	248 1.0×	139 0.7×	29	904
Marie‐Pierre Galais France	14	784 1.0×	662 1.5×	434 1.8×	250 1.1×	238 1.2×	38	1.3k
Elena Ongaro Italy	15	495 0.6×	304 0.7×	134 0.5×	153 0.6×	273 1.4×	38	878
Katrina S. Pedersen United States	15	661 0.8×	220 0.5×	293 1.2×	149 0.6×	202 1.0×	73	970
Janja Ocvirk Slovenia	17	1.0k 1.2×	376 0.9×	231 0.9×	179 0.8×	156 0.8×	69	1.3k
Júlio Oliveira Portugal	18	502 0.6×	412 0.9×	234 1.0×	146 0.6×	283 1.4×	41	1.1k
Dongmei Ji China	15	539 0.7×	463 1.1×	163 0.7×	196 0.8×	392 2.0×	92	1.2k
Kalliopi Andrikou Italy	16	534 0.7×	287 0.7×	164 0.7×	123 0.5×	189 0.9×	54	837
Minaxi Jhawer United States	11	484 0.6×	383 0.9×	160 0.7×	169 0.7×	305 1.5×	14	842

Countries citing papers authored by Satoshi Yuki

Since Specialization

Citations

This map shows the geographic impact of Satoshi Yuki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Satoshi Yuki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Satoshi Yuki more than expected).

Fields of papers citing papers by Satoshi Yuki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Satoshi Yuki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Satoshi Yuki. The network helps show where Satoshi Yuki may publish in the future.

Co-authorship network of co-authors of Satoshi Yuki

This figure shows the co-authorship network connecting the top 25 collaborators of Satoshi Yuki. A scholar is included among the top collaborators of Satoshi Yuki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Satoshi Yuki. Satoshi Yuki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nakamura, Michio, Kentaro Sawada, Kazuteru Hatanaka, et al.. (2023). Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101). Journal of Clinical Medicine. 12(4). 1596–1596. 1 indexed citations

Kato, Takeshi, Hideaki Bando, Yuichiro Tsukada, et al.. (2023). P-172 VOLTAGE cohort D: Preoperative chemoradiotherapy followed by consolidation nivolumab plus ipilimumab in patients with locally advanced rectal cancer. Annals of Oncology. 34. S77–S77. 1 indexed citations

Yuki, Satoshi, Takeshi Kawakami, Takatsugu Ogata, et al.. (2023). 615P The impacts of starting regorafenib dose on treatment outcomes in metastatic colorectal cancer. Annals of Oncology. 34. S441–S442. 1 indexed citations

Matoba, Ryo, Satoshi Yuki, Manabu Shiozawa, et al.. (2023). The BEETS (JACCRO CC-18) Trial: An Observational and Translational Study of BRAF -Mutated Metastatic Colorectal Cancer. Future Oncology. 19(17). 1165–1174. 2 indexed citations

Kajiwara, Takeshi, Tomohiro Nishina, Yoshiaki Nakamura, et al.. (2023). Sidedness-Dependent Prognostic Impact of Gene Alterations in Metastatic Colorectal Cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN). Cancers. 15(21). 5172–5172. 1 indexed citations

Kawakami, Takeshi, Toshiki Masuishi, Yasuyuki Kawamoto, et al.. (2022). The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study. Cancer Medicine. 11(11). 2184–2192. 1 indexed citations

Kawamoto, Yasuyuki, Satoshi Yuki, Takashi Meguro, et al.. (2022). Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201). The Oncologist. 27(5). 340–e374. 5 indexed citations

Saito, Rika, Yasuyuki Kawamoto, Mutsumi Nishida, et al.. (2022). Usefulness of ultrasonography and elastography in diagnosing oxaliplatin-induced sinusoidal obstruction syndrome. International Journal of Clinical Oncology. 27(11). 1780–1790. 2 indexed citations

Komatsu, Yoshito, Yasuyuki Kawamoto, Rika Saito, et al.. (2020). Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer. Medicine. 99(39). e22250–e22250. 21 indexed citations

10.

Kawazoe, Akihito, Yasutoshi Kuboki, Eiji Shinozaki, et al.. (2020). Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial). Clinical Cancer Research. 26(22). 5887–5894. 66 indexed citations

11.

Yuki, Satoshi, Hideaki Bando, Yuichiro Tsukada, et al.. (2020). SO-37 Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stability and microsatellite instability-high, locally advanced rectal cancer (EPOC 1504). Annals of Oncology. 31. S230–S231. 11 indexed citations

12.

Yoshino, Takayuki, Hideaki Bando, Yuichiro Tsukada, et al.. (2019). VOLTAGE: Investigator-initiated clinical trial of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable locally advanced rectal cancer. Annals of Oncology. 30. iv129–iv129. 4 indexed citations

13.

Kawamoto, Yasuyuki, Yoshito Komatsu, Satoshi Yuki, et al.. (2017). Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer. BMC Cancer. 17(1). 837–837. 4 indexed citations

14.

Nakamura, Michio, Atsushi Ishiguro, Satoshi Yuki, et al.. (2017). A Prospective Observational Study on Effect of Short-Term Periodic Steroid Premedication on Bone Metabolism in Gastrointestinal Cancer (ESPRESSO-01). The Oncologist. 22(5). 592–600. 24 indexed citations

15.

Komatsu, Yoshito, Atsuo Takashima, Tadamichi Denda, et al.. (2017). Treatment outcome according to tumor RAS mutation status in TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer. Annals of Oncology. 28. v158–v158. 4 indexed citations

16.

Komatsu, Yoshito, Kentaro Sawada, Toshiya Muranaka, et al.. (2016). P-168 Retrospective comparison of efficacy and safety of docetaxel and weekly-paclitaxel as 2nd-line chemotherapy for patients with unresectable or recurrent esophageal cancer. Annals of Oncology. 27. ii50–ii50. 2 indexed citations

17.

Fuse, Nozomu, Yasutoshi Kuboki, Takeshi Kuwata, et al.. (2015). Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients. Gastric Cancer. 19(1). 183–191. 94 indexed citations

18.

Yuki, Satoshi, et al.. (2012). Clinical Outcome of Japanese Metastatic Colorectal Cancer Patients Harbouring the KRAS p.G13D Mutation Treated with Cetuximab + Irinotecan. Japanese Journal of Clinical Oncology. 42(12). 1146–1151. 15 indexed citations

19.

Shitara, Kohei, Takashi Ura, Keitaro Matsuo, et al.. (2011). Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer. European Journal of Cancer. 47(18). 2673–2680. 1 indexed citations

20.

Asaka, Masahiro, Yasushi Sakata, Masaki Munakata, et al.. (2010). PHASE II TRIAL OF COMBINED CHEMOTHERAPY WITH IRINOTECAN, S-1, AND BEVACIZUMAB IN PATIENTS WITH METASTATIC COLORECTAL CANCER. Annals of Oncology. 21. 197. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact